Immunohistochemical expression of cyclooxygenage-2 in melanocytic skin lesions

International Journal of Dermatology

Volumn 50, Issue 1, 2011, Pages 24-29

  Minami, Shoichiro ^a,b   Lum, Christopher A ^a   Kitagawa, Kevin M ^a   Namiki, Thomas S ^a  

^a UNIVERSITY OF HAWAII   (United States)

^b HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2;

ADULT; AGED; ARTICLE; CELL MATURATION; CLINICAL ASSESSMENT; DIFFERENTIAL DIAGNOSIS; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MALIGNANT LENTIGO; MELANOCYTIC SKIN LESION; MELANOMA; PIGMENTED NEVUS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SKIN DISEASE; TUMOR DIFFERENTIATION;

ADULT; AGED; CYCLOOXYGENASE 2; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MELANOMA; MIDDLE AGED; NEVUS; PROGNOSIS; RETROSPECTIVE STUDIES; SKIN; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 78650554580     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2010.04628.x     Document Type: Article

References (30)

1. Leong J, Hughes-Fulford M, Rakhlin N, et al. Cyclooxygenases in human and mouse skin and cultured human keratinocytes: association of COX-2 expression with human keratinocyte differentiation. Exp Cell Res 1996; 224: 79-87.
2. Kagoura M, Toyoda M, Matsui C, et al. Immunohistochemical expression of cyclooxygenase-2 in skin cancers. J Cutan Pathol 2001; 28: 298-302.
3. Kim KH, Park EJ, Seo YJ, et al. Immunohistochemical study of cyclooxygenase-2 and p53 expression in skin tumors. J Dermatol 2006; 33: 319-325.
4. Denkert C, Köbel M, Berger S, et al. Expression of cyclooxygenase 2 in human malignant melanoma. Cancer Res 2001; 61: 303-308.
5. Goulet A-C, Einsphar JG, Alberts DS, et al. Analysis of cyclooxygenase 2 (COX-2) expression during malignant melanoma progression. Cancer Biol Ther 2003; 2: 713-718.
6. Bianchini F, Massi D, Marconi C, et al. Expression of cyclo-oxygenase-2 in macrophages associated with cutaneous melanoma at different stages of progression. Prostaglandins Other Lipid Mediat 2007; 83: 320-328.
7. Kuźbicki Ł, Sarnecka A, Chwirot BW. Expression of cyclooxygenase-2 in benign naevi and during human cutaneous melanoma progression. Melanoma Res 2006; 16: 29-36.
8. Chwirot BW, Kuźbicki Ł. Cyclooxygenase-2 (COX-2): first immunohistochemical marker distinguishing early cutaneous melanomas from benign melanocytic skin tumors. Melanoma Res 2007; 17: 139-145.
9. Lejeune FJ, Monnier Y, Rüegg C. Complete and long-lasting regression of disseminated multiple skin melanoma metastases under treatment with cyclooxygenase-2 inhibitor. Melanoma Res 2006; 16: 263-265.
10. Wilson KS. Clinical activity of celecoxib in metastatic malignant melanoma. Cancer Invest 2006; 24: 740-746.
11. Zhan H, Zheng H. The role of topical cyclo-oxygenase-2 inhibitors in skin cancer: treatment and prevention. Am J Clin Dermatol 2007; 8: 195-200.
12. Patel MJ, Ulrich C, Forschner T. Genetically determined susceptibility to COX-2 inhibitors: a report of exaggerated responders to diclofenac 3% gel in the treatment of actinic keratoses. Br J Dermatol 2007; 156(Suppl): 57-61.
13. Fenwick SW, Toogood GJ, Lodge JP, et al. The effect of the selective cyclooxygenase-2 inhibitor rofecoxib on human colorectal cancer liver metastases. Gastroenterology 2003; 125: 716-729.
14. Altorki NK, Keresztes RS, Port JL, et al. Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer. J Clin Oncol 2003; 21: 2645-2650.
15. Rini BI, Weinberg V, Dunlap S, et al. Maximal COX-2 immunostaining and clinical response to celecoxib and interferon alpha therapy in metastatic renal cell carcinoma. Cancer 2006; 106: 566-575.
16. Mrozek E, Kloos RT, Ringel MD, et al. Phase II study of celecoxib in metastatic differentiated thyroid carcinoma. J Clin Endocrinol Metab 2006; 91: 2201-2204.
17. Buckman SY, Gresham A, Hale P, et al. COX-2 expression is induced by UVB exposure in human skin: implication for the development of skin cancer. Carcinogenesis 1998; 19: 723-729.
18. Nijsten T, Colpaert CG, Vermeulen PB, et al. Cyclooxygenase-2 expression and angiogenesis in squamous cell carcinoma of the skin and its precursors: a paired immunohistochemical study of 35 cases. Br J Dermatol 2004; 151: 837-845.
19. Curtin JA, Busam K, Pinkel D, et al. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006; 24: 4340-4346.
20. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-954.
21. Poynter JN, Elder JT, Fullen DR, et al. BRAF and NRAS mutations in melanoma and melanocytic nevi. Melanoma Res 2006; 16: 267-273.
22. Thomas NE, Edmiston SN, Alexander A, et al. Number of nevi and early-life ambient UV exposure are associated with BRAF-mutant melanoma. Cancer Epidemiol Biomarkers Prev 2007; 16: 991-997.
23. T1799A(V600E) mutation in primary melanoma. J Invest Dermatol 2007; 127: 900-905.
24. Kumar R, Angelini S, Snellman E, et al. BRAF mutations are common somatic events in melanocytic nevi. J Invest Dermatol 2004; 122: 342-348.
25. Fullen DR, Poynter JN, Lowe L, et al. BRAF and NRAS mutations in spitzoid melanocytic lesions. Mod Pathol 2006; 19: 1324-1332.
26. Bastian BC, Wesselmann U, Pinkel D, et al. Molecular cytogenetic analysis of Spitz nevi shows clear difference to melanoma. J Invest Dermatol 1999; 113: 1065-1069.
27. Bastian BC, Olshen AB, LeBoit PE, et al. Classifying melanocytic tumors based on DNA copy number changes. Am J Pathol 2003; 163: 1765-1770.
28. Elder D, Elenitsas R. Benign pigmented lesions and malignant melanoma. In: Elder D, Elenitsas R, Jaworsky C, Johnson B Jr, eds. Lever's Histopathology of the Skin, 8th edn. Philadelphia, PA; New York, NY: Lippincott-Raven, 1997: 625-684.
29. Vogt T, McClelland M, Jung B, et al. Progression and NSAID-induced apoptosis in malignant melanomas are independent of cyclooxygenase II. Melanoma Res 2001; 11: 587-599.
30. Ramirez CC, Ma F, Federman DG, et al. Use of cyclooxygenase inhibitors and risk of melanoma in high-risk patients. Dermatol Surg 2005; 31: 748-752.